Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Invios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"invIOs Goes Live with Unique Cell Therapy Platform and Clinical-Stage Immuno-Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Invios"},{"orgOrder":0,"company":"Invios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"invIOs To Present Data From Clinical Stage Cbl-b Program At SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Invios"},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"invIOs Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Invios"},{"orgOrder":0,"company":"Tubepharma","sponsor":"Oncomatryx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncomatryx Acquires Tube Pharmaceuticals GmbH to Consolidate its Pioneering Pipeline of ADCs Targeting the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Tubepharma"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Invios

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              invIOs Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding

              Details:

              The funding will be used for a Phase 1b trial of its novel autologous cell therapy, APN401, an innovative approach that leverages invIOs’s proprietary EPiC cell therapy platform, in patients with solid tumors.

              Lead Product(s): APN401

              Therapeutic Area: Oncology Product Name: APN401

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Austrian Research Promotion Agency

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding September 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tubepharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oncomatryx Acquires Tube Pharmaceuticals GmbH to Consolidate its Pioneering Pipeline of ADCs Targeting the Tumor Microenvironment

              Details:

              Through the acquisition, Oncomatryx will foster its leadership in ADCs targeting the tumor microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class ADC targeting cancer-associated fibroblasts.

              Lead Product(s): OMTX705,Pembrolizumab

              Therapeutic Area: Oncology Product Name: OMTX705

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Oncomatryx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition May 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Invios

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              invIOs To Present Data From Clinical Stage Cbl-b Program At SITC 2022

              Details:

              APN401 (siRNA-transfected peripheral blood mononuclear cells) is an Autologous Cell Therapy using siRNA mediated silencing of Cbl-b resulting in highly activated tumor-reactive white blood cells.

              Lead Product(s): siRNA-transfected Peripheral Blood Mononuclear Cells

              Therapeutic Area: Oncology Product Name: APN401

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Invios

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              invIOs Goes Live with Unique Cell Therapy Platform and Clinical-Stage Immuno-Oncology Pipeline

              Details:

              The first clinically validated target is the immune master-checkpoint Cbl-b; the clinical-stage lead candidate APN401 will show results in the near term on safety with data from an ongoing Phase 1b trial.

              Lead Product(s): APN401

              Therapeutic Area: Oncology Product Name: APN401

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY